The Impact of Radiotherapy on Oligometastatic Cancer
Recruiting now
Conditions studied: Metastasis, Metastatic Breast Cancer, Metastatic Prostate Cancer, Metastatic Colorectal Cancer, Metastatic Lung Cancer
In brief
Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR). However, there are few studies, and there is no defined clinical standard, nor are the radiobiological mechanisms that contribute to treatment response well understood. The focus should be on generating evidence to guide the personalization of radiotherapy beyond solely technological and anatomical precision. This could be achieved by recollecting clinical and biological data from patients that undergo this treatment and analyzing them to ultimately predict, with the help of artificial intelligence, which patients will be the most beneficiary and improve their survival rate.
Key facts
- Study ID
- NCT05933876
- Run by
- Institut Investigacio Sanitaria Pere Virgili
- People needed
- 2000
- Starts
- 2022-12-01
- Expected to finish
- 2037-12-31
- Last updated by the study team
- 2024-11-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologic confirmation of primary tumor: breast, prostate, lung, colorectal.
- 18 years old or older.
- Up to five metastases located in the bone, lung, node, liver or brain.
- Eastern Cooperative Oncology Group (ECOG) Performance Status Scale 0 or 1.
You may not qualify if…
- Non-melanoma skin cancer.
- Previous radiotherapy in the same anatomic location.
- Presence of vascular collagen disease.
- Pregnancy or lactation at the time of inclusion.
Where it is running
- Hospital Universitari Sant Joan de Reus — Reus, Tarragona, Spain (enrolling)
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau — Barcelona, Barcelona, Spain
- Hospital Universitari Vall d'Hebron — Barcelona, Barcelona, Spain
- Institut Català d'Oncologia — Barcelona, Barcelona, Spain
- Hospital Universitario Virgen de las Nieves — Granada, Granada, Spain
- Hospital Universitari Arnau de Vilanova — Lleida, Lleida, Spain
- Hospital de La Luz — Madrid, Madrid, Spain
- Hospital Ruber Internacional — Madrid, Madrid, Spain
- Hospital Universitario HM Sanchinarro — Madrid, Madrid, Spain
- Hospital Universitario Quirónsalud — Madrid, Madrid, Spain
- Hospital Universitario Rey Juan Carlos — Madrid, Madrid, Spain
- Hospital Universitario Virgen Macarena — Seville, Sevilla, Spain
- Hospital Clínico Universitario de Valencia — Valencia, Valencia, Spain
- Hospital General Univesitario de Valencia — Valencia, Valencia, Spain
- Hospital Universitari Miguel Servet — Zaragoza, Zaragoza, Spain
- Hospital del Mar — Barcelona, Spain
- Hospital Provincial de Castellón — Castellon, Spain
- Institut Català d'Oncologia — Girona, Spain
- Hospital Universitario Ramón y Cajal — Madrid, Spain
- Complejo Hospitalario Universitario Albacete — Albacete, Albacete, Spain
- Hospital de Terrassa — Terrassa, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.